dat 201

ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.

EGFR-IN-451 is an EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis.

ABT-925 is a selective dopamine D3 receptor (DRD3) antagonist with an in vitro affinity approximately 100 times higher for dopamine D3 receptors than for D2 receptors.